Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Immune System Diseases
Decision date
30/10/2025
Enrollment target
10
Sites
Netherlands
Condition studied
Graves' Orbitopathy
Investigational medicinal product(s)
68GA-FAPI-46
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
FAPI uptake in active GO versus inactive GO on PET-MRI
Endpoint detail
Relation MRI results (edema), clinical symptoms, and lab values to FAPI-uptake on PET.
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.